CASE REPORTS in HAEMATOLOGY (Paper co-edited with the European LeukemiaNet)

A new case of t(16;21)(q24;q22) in a secondary AML-M2 following breast cancer therapy

Helene Bruyere, Wilson Yeung, Peter Tsang

Clinics

Age and sex :	61 year(s) old female patient.
Previous History :	no preleukemia
	no inborn condition of note
Organomegaly :	no hepatomegaly ; no splenomegaly ; no enlarged lymph nodes ; no central nervous system involvement

Blood

WBC : 2.4 x 109/l; Hb : 10.7 g/dl; platelets : 48 x 109/l; blasts : 2%

Cyto pathology classification

Cytology : AML-M2

Immunophenotype : Positive for HLA-DR, CD34, CD117, CD13, CD33, MPO, CD56 and CD19 ; Partial Tdt ; Negative for CD7

Precise diagnosis : Hypoplastic AML, therapy related

Survival

Date of diagnosis: 04-2005

Treatment : Three cycles of AraC and Danuribicin ; Related bone marrow transplantation planned for September 2005

Complete remission : None

Status : Alive 07-2005

Survival : 3 month(s)

Karyotype

Sample : Bone marrow ; culture time : 24 h ; banding : GTG

Results : 47,XX,+8,t(16;21)(q24;q22)[13]/46,XX[3]

Partial karyotype showing the t(16;21) and a +8

Comments

The t(16;21)(q24;q22) is mainly found in t-MDS/t-AML (14/16 cases (1-10)), following breast cancer therapy (five cases (7,8,10)), lymphoma (four cases), Hodgkin's disease, lung and oviductal cancers and AML-M3 (one case each). Trisomy 8, the secondary change found in the current case, is also reported in most if not all patients with previous breast cancer (7,8,10). To note, three out of five patients had lymphoid positive antigenes (5,7, current case). All of the nine patients whose treatments were reported (3-9), plus the current case, were treated with a combination of alkylating agents and topoisomerase II inhibitors, +/- radiotherapy.

Internal links

Atlas Card	t(16;21)(q24;q22)
Case Report	A case of trisomy 8 and loss of the Y-chromosome as secondary aberrations in a ten year old boy with de novo AML FAB M2 and t(16;21)(q24;q22)

Bibliography

Cytogenetics of childhood acute nonlymphocytic leukemia.

Raimondi SC, Kalwinsky DK, Hayashi Y, Behm FG, Mirro J Jr, Williams DL

Cancer genetics and cytogenetics. 1989 ; 40 (1) : 13-27.

PMID 2758395

Metaphase fluorescence in situ hybridization (FISH) in the follow-up of 60 patients with haemopoietic malignancies.

Nylund SJ, Ruutu T, Saarinen U, Knuutila S

British journal of haematology. 1994 ; 88 (4) : 778-783.

PMID 7819102

Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma.

Traweek ST, Slovak ML, Nademanee AP, Brynes RK, Niland JC, Forman SJ

Blood. 1994 ; 84 (3) : 957-963.

PMID 8043877

Secondary acute myeloblastic leukemia with t(16;21) (q24;q22). involving the AML1 gene.

Berger R, Le Coniat M, Romana SP, Jonveaux P

Hematology and cell therapy. 1996 ; 38 (2) : 183-186.

PMID 8932000

A recurrent translocation, t(16;21)(q24;q22), associated with acute myelogenous leukemia: identification by fluorescence in situ hybridization.

Shimada M, Ohtsuka E, Shimizu T, Matsumoto T, Matsushita K, Tanimoto F, Kajii T

Cancer genetics and cytogenetics. 1997 ; 96 (2) : 102-105.

PMID 9216714

A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide.

Takeda K, Shinohara K, Kameda N, Ariyoshi K

International journal of hematology. 1998 ; 67 (2) : 179-186.

PMID 9631585

AML1-MTG16 fusion gene in therapy-related acute leukemia with t(16;21)(q24;q22): two new cases.

Salomon-Nguyen F, Busson-Le Coniat M, Lafage Pochitaloff M, Mozziconacci J, Berger R, Bernard OA

Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2000 ; 14 (9) : 1704-1705.

PMID 10995019

AML1/MTG16 fusion gene from a t(16;21)(q24;q22) translocation in treatment-induced leukemia after breast cancer.

La Starza R, Sambani C, Crescenzi B, Matteucci C, Martelli MF, Mecucci C

Haematologica. 2001 ; 86 (2) : 212-213.

PMID 11224496

A pediatric case of secondary leukemia associated with t(16;21)(q24;q22) exhibiting the chimeric AML1-MTG16 gene.

Kondoh K, Nakata Y, Furuta T, Hosoda F, Gamou T, Kurosawa Y, Kinoshita A, Ohki M, Tomita Y, Mori T

Leukemia & lymphoma. 2002 ; 43 (2) : 415-420.

PMID 11999578

21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop.

Slovak ML, Bedell V, Popplewell L, Arber DA, Schoch C, Slater R

Genes, chromosomes & cancer. 2002 ; 33 (4) : 379-394.

PMID 11921272

Contributor(s)

Written

08-2005

Helene Bruyere, Wilson Yeung, Peter Tsang

Citation

This paper should be referenced as such :

Bruyere H, Yeung W, Tsang P . A new case of t(16;21)(q24;q22) in a secondary AML-M2 following breast cancer therapy. Atlas Genet Cytogenet Oncol Haematol. August 2005 . URL : http://AtlasGeneticsOncology.org/Reports/1621BruyereID100013.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology

indexed on : Wed Sep 24 21:09:51 2008

For comments and suggestions or contributions, please contact us